3 unknown. 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Not applicable | 1 | Unknown 1 |
Follow Xiaohua Wu MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment Fluzoparib+Apatinib, Fluzoparib Monotherapy - Relapsed Ovarian Cancer | Phase 2 | Unknown | Xiaohua Wu MD | 132 | 2022-08-01 | 2022-07-29 |
| Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies Mecapegfilgrastim Injection - Gynecologic Malignant Tumor | Not applicable | Unknown | Xiaohua Wu MD | 150 | 2021-05-01 | 2021-02-26 |
| Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer Etoposide, Cyclophosphamide, Carboplatin - Ovarian Cancer | Phase 2 | Unknown | Xiaohua Wu MD | 130 | 2015-11-01 | 2022-07-27 |
Ovarian Neoplasms (2) · Neutropenia (1)
Carboplatin (1) · Cyclophosphamide (1) · Etoposide (1) · pegylated granulocyte colony-stimulating factor (1)
China (2)
Xiaohua WU, PhD & MD (1) · Xiaohua Wu, MD&PHD (1) · Xiaohua Wu, Ph.D., MD (1)